Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors

Journal of Nuclear Medicine

Volumn 51, Issue 10, 2010, Pages 1524-1531

  Menda, Yusuf ^a,b   O'Dorisio, M Sue ^a,b   Kao, Simon ^a,b   Khanna, Geetika ^c   Michael, Stacy ^a   Connolly, Mary ^d   Babich, John ^e   O'Dorisio, Thomas ^a,b   Bushnell, David ^a,f   Madsen, Mark ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e A Subsidiary of Lantheus Holdings   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Children; Radiolabeled peptide; Somatostatin; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; DIETHYLENETRIAMINEPENTAACETIC ACID DEXTRO PHENYLALANYL OCTREOTIDE IN 111; DOTATOC Y 90; LYSINE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; BONE MARROW CELL; BRONCHUS CARCINOID; CANCER CHEMOTHERAPY; CARCINOID SYNDROME; CHILD; CHOROID PLEXUS TUMOR; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE TUMOR; FEMALE; GASTRINOMA; GLOMERULUS FILTRATION RATE; HEMATOPOIETIC STEM CELL; HUMAN; HYPONATREMIA; MALE; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE ENDOCRINE NEOPLASIA; NAUSEA; NEPHROTOXICITY; NEUROBLASTOMA; OUTCOME ASSESSMENT; PARAGANGLIOMA; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PHASE 1 CLINICAL TRIAL; PINEAL BODY TUMOR; PRESCHOOL CHILD; PRIORITY JOURNAL; RENAL PROTECTION; SCHOOL CHILD; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; OCTREOTIDE; RADIATION INJURIES; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; RISK ASSESSMENT; YOUNG ADULT;

EID: 79851480443     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.075226     Document Type: Article

References (36)

1. Fruhwald MC, O'Dorisio MS, Pietsch T, Reubi JC. High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy. Pediatr Res. 1999;45:697-708. (Pubitemid 29203604)
2. Albers AR, O'Dorisio MS, Balster DA, et al. Somatostatin receptor gene expression in neuroblastoma. Regul Pept. 2000;88:61-73. (Pubitemid 30114387)
3. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-846. (Pubitemid 32662546)
4. de Herder WW, Kwekkeboom DJ, Feelders RA, et al. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary. 2006;9:243-248. (Pubitemid 44742286)
5. Pashankar FD, O'Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. J Nucl Med. 2005;46(suppl 1):55S-61S.
6. Khanna G, O'Dorisio MS, Menda Y, et al. Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. Pediatr Blood Cancer. 2008;50:561-566. (Pubitemid 351155825)
7. Fruhwald MC, Rickert CH, O'Dorisio MS, et al. Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging. Clin Cancer Res. 2004;10:2997-3006. (Pubitemid 38619675)
8. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417-418. (Pubitemid 28064170)
9. Kwekkeboom DJ, Teunissen JJ, Kam BL, Valkema R, de Herder WW, Krenning EP. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am. 2007;21:561-573. (Pubitemid 46843516)
10. 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer. 2005;44:232-239.
11. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008;22:436-448. (Pubitemid 351272752)
12. Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003;56:28-39. (Pubitemid 36403674)
13. Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 2007;6:1073-1085. (Pubitemid 350116703)
14. Mackley HB, Videtic GM. Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park). 2006;20:1537-1543; discussion 1544-1535, 1549.
15. 177Lu- octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007;34:1219-1227.
16. 90Y-DOTA0,Tyr3] octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm. 2003;18:619-625.
17. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447. (Pubitemid 29515605)
18. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207-216.
19. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S-66S.
20. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-73.
21. 177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
22. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997;89:1138-1147. (Pubitemid 27337928)
23. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
24. Loevinger RBT, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York: The Society of Nuclear Medicine; 1991.
25. Hurwitz CA, Relling MV, Weitman SD, et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol. 1993;11:2324-2329.
26. 3-octreotate. J Nucl Med. 2005;46(suppl 1):83S-91S.
27. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9-15. (Pubitemid 36692887)
28. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med. 1994;35:152-156. (Pubitemid 24018459)
29. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
30. 111In-pentetreotide SPECT imaging. Nucl Med Commun. 2004;25:253-257.
31. 68Ga-DOTA-Tyr3- Octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427-1434.
32. 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med. 2003;44:1556-1560.
33. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med. 1999;40:762-767.
34. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386-1392.
35. 111In- DTPA-octreotide. Eur J Nucl Med. 2001;28:1743-1750.
36. Hindorf C, Chittenden S, Causer L, Lewington VJ, Macke HR, Flux GD. Dosimetry for 90Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm. 2007;22:130-135. (Pubitemid 46697375)